Thera-SAbDab

GANITUMAB

>   Structural Summary
TherapeuticGanitumab
TargetIGF1R
Heavy ChainQVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS
Light ChainDVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-III
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedAmgen%3BMillennium%3BNantWorks%3BNational Cancer Institute %28USA%29%3BNovartis%3BTakeda%3BTakeda Oncology%3BUCLAs Jonsson Comprehensive Cancer Center
Conditions Approvedna
Conditions ActiveEwing%27s sarcoma%3BSolid tumours%3BRhabdomyosarcoma
Conditions DiscontinuedBreast cancer%3BColorectal cancer%3BSarcoma%3BSmall cell lung cancer%3BNon-small cell lung cancer%3BPancreatic cancer%3BProstate cancer
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy